(Corrects the number of patients to “about 650” from “about 325”)
Aug 19 (Reuters) - GTx Inc said its experimental drug to treat muscle wasting in cancer patients was not effective in improving body mass in late-stage trials.
A 3-mg dose of the drug, enobosarm, was tested on about 650 patients with non-small cell lung cancer - the most common form of lung cancer.
There is no approved cure for cancer-induced muscle wasting which causes decreased physical function, fatigue and weight loss. (Reporting by Pallavi Ail in Bangalore; Editing by Saumyadeb Chakrabarty)